坐落在高新区的合源生物科技股份有限公司，是国内免疫细胞治疗创新药研发和产业化领域的领军企 业，公司首款产品"源瑞达"填补了成人急性淋巴细胞白血病治疗的空白，去年11月，其治疗淋巴瘤的新 适应症获批，成为国内目前唯一覆盖白血病与淋巴瘤两大血液肿瘤适应症的CAR-T（嵌合抗原受体T细 胞）产品。 "公司的快速发展，离不开高新区这片创新沃土所提供的全方位、系统性支持。比如，围绕企业全生命 周期，高新区提供了从事前咨询、事中协调到事后服务的全方位创新服务，让我们成功取得了京津冀地 区首张细胞领域《药品生产许可证》。此外，高新区产业引导基金参与公司多轮融资，人才引进、评价 激励等方面的创新举措，帮助我们吸引了海内外顶尖科研人才。"合源生物政府事务总监朱瑞贺表示， 接下来，企业将在拓展适应症、扩增产能、推进全球布局等领域持续深耕。 眼下，高新区聚集了100余家细胞及基因治疗产业链上下游企业，形成了包含细胞提取制备、细胞存 储、冷链物流、创新研发、小试中试、审评审批、临床应用等环节的全产业链。此外，在创新药物、医 疗器械、医药服务等领域多点开花，产业实力稳步提升。 （来源：天津日报） 转自：天津日报 本报讯（记者 马晓冬） ...

作为全国首个疫苗检验单体建设项目，中心建筑面积1.6万平方米，设有病毒疫苗室、细菌疫苗室、动 物实验室等5个疫苗检验所需的专业实验室及配套设施，可覆盖京产疫苗在产品种的全部检验项目。同 时，中心满足新型疫苗、新型抗体药物、细胞基因治疗产品等生物新药研发需求，实现对北京市生物制 品创新研发的全链条质控技术支持。 北京作为全国疫苗研发与生产的重要集聚地，拥有8家疫苗生产企业、品种占全国40%以上，生产供应 的疫苗数量居全国首位。2022年市药品检验研究院作为全国四家国家疫苗批签发网络实验室之一，顺利 通过世卫组织国家疫苗监管体系（NRA）评估，2024年成为国内首家通过世卫组织PQ预认证的省级药 检机构，率先全面实现检验业务信息化。目前已具备28个疫苗品种全项检验能力，获国家药监局疫苗批 签发授权9个，疫苗批签发检验能力稳居全国各省首位。 北京商报讯（记者 王寅浩 宋雨盈）12月26日，北京市疫苗检验中心在中关村生命科学园正式揭牌启 用，将满足每年4000—4500批次的疫苗批签发检验需求，具备未来5—10年新上市疫苗的批签发检验能 力，预计2026年一季度开始承担已获授权的京产9种疫苗批签发工作。 北京市药检院 ...

人民财讯12月17日电，西安市人民政府办公厅印发《促进生物医药产业能力提升实施方案(2025—2027 年)》，提出到2027年，全市生物医药产业规模达到400亿元，其中中药、化药生物药、医疗器械、消费 医疗产业链群分别达到90亿元、120亿元、60亿元、130亿元。规模以上企业突破130户，培育年产值超 80亿元、30亿元、20亿元、10亿元以上企业1户、1户、2户、4户，推动2户企业上市。 ...

Core Insights - The article highlights the successful development and approval of the innovative drug "Taretnib" by Baoyuan Pharmaceutical, marking a significant milestone for Chinese pharmaceutical innovation on the global stage [2][6] Group 1: Drug Development and Approval - Taretnib is the first Class 1 innovative drug to emerge from the Hangzhou Medical Port, recently receiving approval from Japan's Ministry of Health, Labor and Welfare, following its approval in the United States [2] - The drug targets a specific genetic mutation in non-small cell lung cancer, which affects only 1% to 3.4% of patients, yet represents a breakthrough opportunity for Chinese innovation in pharmaceuticals [3] Group 2: Company Strategy and Collaboration - Baoyuan Pharmaceutical adopts a "global rights, global development" strategy, collaborating with partners in China, South Korea, and Japan to enhance clinical development and commercialization efforts [4] - The company has successfully navigated the drug approval process, benefiting from China's accelerated drug approval system, particularly under the "14th Five-Year Plan" which emphasizes support for the biopharmaceutical industry [6] Group 3: Industry Growth and Impact - The biopharmaceutical industry in Hangzhou has seen significant growth, with the number of pharmaceutical production companies increasing from 94 to 133 and wholesale companies from 167 to 318 over the past five years, reflecting an average growth rate of 83% [7] - The successful acquisition of Baoyuan Pharmaceutical by a U.S. biopharmaceutical company underscores the global recognition of Chinese innovative drugs, completing a cycle of internationalization from development to market acceptance [7]

Core Viewpoint - The Lishan International Biopharmaceutical Production Base has officially commenced operations, marking a significant advancement in the high-quality development of the biopharmaceutical industry in Jinan City, China [1] Group 1: Infrastructure and Location - The base is located in the convenient transportation area of the Lixia Economic Development Zone, adjacent to major roads and surrounded by planned routes, combining natural environment and location advantages [3] - The total area of the park is approximately 113 acres, with a planned total construction area of 180,000 square meters, designed based on M1 standard industrial land [3] Group 2: Industry Focus and Ecosystem - The base aims to create a complete industrial ecosystem by sharing resources with the Lishan International Cell Medicine Industrial Park, providing comprehensive support services for resident enterprises [5] - It focuses on high-value biopharmaceutical fields such as vaccines, antibodies, and cell gene drugs, while also expanding into bioproducts, traditional Chinese medicine, and medical devices [5] Group 3: Business Development and Future Plans - Currently, the base has attracted over 10 leading and high-quality enterprises in the biopharmaceutical industry, creating a distinct industrial agglomeration effect [6] - Future plans include promoting the establishment of more leading biopharmaceutical companies, enhancing the dual-driven model of R&D and production, and building a comprehensive industrial platform [6]

Core Viewpoint - The Heze Luxi New Area has made significant progress in drug safety regulation and industry development, addressing public concerns and enhancing safety awareness through various initiatives [1][5]. Group 1: Drug Safety Regulation - The Luxi New Area has implemented a dual approach of "promotion + training" to enhance public and industry personnel's safety awareness, conducting multiple public outreach events and training sessions [2]. - A comprehensive regulatory system has been established, focusing on risk management and local oversight, with over 1,600 law enforcement personnel deployed to inspect 463 drug operating units this year [3]. - The "Code for Assurance" platform has achieved a 100% registration rate for drug operating units, ensuring traceability and quality control of drugs [3]. Group 2: Industry Development - The biopharmaceutical industry is a key sector in the Luxi New Area, with several major projects completed and new investments signed, totaling 7.51 billion yuan this year [4]. - The area has facilitated the growth of retail pharmacy chains, with 282 drug retail enterprises and a chain rate of 86%, promoting scale and efficiency in the industry [5]. Group 3: Public Engagement and Compliance - The Luxi New Area has strengthened online drug sales regulation, achieving a 100% inspection coverage of 149 online sales enterprises, while advising consumers to purchase from legitimate platforms [5]. - Future efforts will focus on enhancing regulatory services and encouraging public participation in drug safety governance, fostering a collaborative environment for high-quality industry development [5].

Core Viewpoint - The company, Baillie Gifford, has signed a strategic cooperation agreement with Bank of China Sichuan Branch to establish a long-term comprehensive strategic partnership, which includes a commitment to provide no less than 8 billion yuan in credit support for the company's development strategy [1] Group 1 - The strategic cooperation agreement aims to support the company's funding needs in the innovative drug research and development process [1] - The agreement will facilitate the company's strategic layout in the global biopharmaceutical frontier, reinforcing its leading position in fields such as antibody-drug conjugates (ADC) and multi-specific antibodies [1] - This partnership is expected to help both parties seize new opportunities in the global biopharmaceutical industry, achieving mutual benefits and common development [1]

Core Insights - The 2025 China Biotechnology Innovation Conference opened in Chengdu, where the "2024 China Biopharmaceutical Park Competitiveness Evaluation and Analysis Report" was presented, highlighting the competitive landscape of biopharmaceutical parks in China [1] Group 1: Competitiveness Rankings - The "2024 China Biopharmaceutical Park Competitiveness Rankings" revealed that Jiangsu Province holds 17 out of the top 50 spots, an increase of 3 from the previous year [1] - The rankings assess biopharmaceutical parks based on multiple dimensions including environment, industry, technology, talent, and cooperation, making it one of the most authoritative evaluations of regional biopharmaceutical industry development [1] Group 2: Jiangsu Province Highlights - Suzhou Industrial Park continues to lead with a comprehensive competitiveness ranking of second nationally, following the Zhongguancun National Independent Innovation Demonstration Zone [1] - Suzhou's talent and cooperation competitiveness are ranked first nationally, solidifying its position in the top tier of biopharmaceutical parks [1] - The biopharmaceutical and health industry is a strategic emerging industry that Suzhou Industrial Park has consistently focused on since its establishment in 2006, with over 2,000 related enterprises and an expected output value of 165.5 billion yuan in 2024 [1] Group 3: Other Notable Parks - Jiangsu Province has three parks in the top 10, with Nanjing Biopharmaceutical Valley ranked 8th and Taizhou High-tech Pharmaceutical Industrial Development Zone ranked 10th [1]

Core Insights - The SAPA-China2025 Pharmaceutical Industry Conference was held in Suzhou High-tech Zone, focusing on innovative drug development, cell/gene therapy, AI in medicine, and high-end formulations, among other areas [1] - The conference attracted over 10,000 participants, including leaders from major multinational pharmaceutical and biotech companies, and aimed to enhance collaboration and investment in the pharmaceutical sector [1] - The conference also established a new think tank for the development of the biopharmaceutical industry in the Suzhou High-tech Zone, which will provide expert support for attracting international technologies and resources [1] Industry Development - Suzhou has implemented a series of policy measures to support the construction of a national advanced manufacturing cluster for biopharmaceuticals and high-end medical devices, gathering over 4,200 related enterprises, including nearly 600 large-scale companies [2] - The biopharmaceutical and high-end medical device cluster in Suzhou was included in the list of 45 national advanced manufacturing clusters, with an industrial output value of nearly 240 billion yuan last year [2] - The Suzhou High-tech Zone is one of the most dynamic areas for technological innovation, housing over 1,400 medical device and biopharmaceutical companies, with an output value exceeding 60 billion yuan and an annual growth rate of over 30% [2]

Core Insights - The meeting focused on innovative industrial investment models in Yunnan, trade services under the "One Village, One Product" initiative, low-altitude economy development, cultural and tourism integration, financial empowerment for industrial upgrades, and the establishment of a credit system for park enterprises [1][2]. Group 1: Industrial Development - The Kunming High-tech Zone has achieved significant results in key industries such as biomedicine and health, new materials from tin and precious metals, and digital economy and intelligent manufacturing [2][3]. - The park management committee aims to clarify the advantages and shortcomings of the semiconductor industry, avoid technological limitations, and leverage green electricity resources for sustainable operations [5]. Group 2: Investment and Collaboration - The discussion included the invitation for the Kunming High-tech Zone and related enterprises to participate in the "2025 One Village, One Product International Commodity Expo" [2]. - Both parties agreed on the need for government guidance in the low-altitude economy sector, combining market-oriented operations by enterprises, and seeking policy support to attract social capital [2][3]. Group 3: Strategic Initiatives - The "One Plus Four Plus N" high-quality development strategy is being actively integrated into the biomedicine sector to promote industrial clustering and resource optimization [5]. - The potential establishment of a mixed-ownership operating company for the low-altitude economy in the high-tech zone was explored [2].